mr. sci. dr. Berisa Hasanbegović

Speaking Sessions

Biografija

PROFESIONALNI INTERESI

Karcinom dojke, pluća i ginekološki karcinomi: sistemski onkološki tretman (kemoterapija, biološka terapija, ciljana terapija, imunoterapija) u neoadjuvantnom, adjuvantnom i metastatskom miljeu.

 

 

Obrazovanje

Maj 2016                              Subspecijalista medicinske onkologije

Januar 2016-                      Doktorski studij, Medicinski fakultet u Sarajevu, Univerzitet u Sarajevu

2014- 2016                          Subspecijalizacija iz medicinske onkologije

Oktobar 2011                     Odbrana magistarskog rada iz medicinskih nauka, tema: karcinom dojke

April 2010.                           Specijalistički ispit iz interne medicine

2006-2010.                          Specijalizacija iz interne medicine

2003 – 2008.                       Postdiplomski studij- smjer eksperimentalno-laboratorijski

Medicinski fakultet u Sarajevu, Univerzitet u Sarajevu, prosjek ocjena 10.0.

Juli 2003.                              Državni ispit za doktora medicine

1993 – 2002.                       Medicinski fakultet u Sarajevu, Univerzitet u Sarajevu,

diplomirala u julu 2002. prosjek tokom studija 8.84.                                 

1989-1993.                          II Gimnazija u Sarajevu

 

Radno iskustvo

2019-        :                          Medicinski fakultet SSST, viši asistent, predmet Onkologija;

2018- 2019:                         Medicinski fakultet SSST, ekspert iz prakse, predmet Onkologija;

2004 –  :                              Klinika za onkologiju Klinički Centar Univerziteta u Sarajevu

Subspecijalista medicinske onkologije na odjelu Medicinska onkologija od 2016.

Specijalista interne medicine na odjelu Medicinska onkologija od 2010.;

Specijalizant interne medicine od 2006-2010.;

Ljekar sekundarac na odjelu Medicinska onkologija od 2004.-2006.

2002 – 2004:                       Farmaceutska kompanija Bosnalijek Sarajevo

Pozicija – stručni saradnik u medicinsko-informativnoj službi,

Sektor Domaći Marketing

1996-1997:                          Demonstrator, Institut za anatomiju, Medicinski fakultet u Sarajevu;

1997-1999:                          Demonstrator, Institut za biohemiju, Medicinski fakultet u Sarajevu.

 

Strani jezici

Tečno poznavanje engleskog i pasivno poznavanje njemačkog jezika.

 

Učešće u seminarima i edukacijama

ESMO (European Society of Medical Oncology) član od 2005

·         Internacionalni kongres studenata medicine, Kairo, Egipat (2000)

  • 13. ECCMID kongres mikrobiologije i infektologije, Glazgov, Škotska (2003)

·         3. Konferencija o karcinomu dojke u Sarajevu (2005), BiH

  • ESEC (ESMO Scientific & Educational Conference), Budimpešta, Mađarska (2005)
  • ESPEN (European Society for Clinical Nutrition and Metabolism) bazični kurs iz enteralne i parenteralne prehrane, Vilnius, Litvanija (2005)
  • 6. Internacionalni Workshop o molekularnoj ciljanoj terapiji karcinoma, Krakov, Poljska (2006)
  • 31. ESMO kongres, Istanbul, Turska (2006)

·         1. Internacionalna Konferencija o karcinomu dojke u Sarajevu, BiH (2007)

  • Internacionalni kurs o bolu, Sarajevo, BiH (2007)
  • 2. Seminar Balkanske onkološke Unije, Volos, Grčka (2007)
  • 44. Kancerološka nedjelja, Beograd, Srbija (2007)
  • 7. Postdiplomski seminar iz kliničke onkologije, Sofija, Bugarska (2008)
  • 10. Svjetski kongres o gastrointestinalnim karcinomima, Barcelona, Španija (2008)
  • Bazična škola ultrazvuka abdomena, KCUS, BiH, (2008)
  • Salzburg Weill Cornell/MSKCC Seminar iz onkologije, Salzburg, Austrija (2008)

·         2. Internacionalna Konferencija o karcinomu dojke u Sarajevu, BiH (April 2009)

  • Salzburg Weill Cornell/MSKCC Seminar iz interne medicine, Salzburg, Austrija (Juni 2009)
  • 3. Seminar Balkanske onkološke Unije, Volos, Grčka (Septembar 2009)
  • Udruženi 15. ECCO/34. ESMO kongres, Berlin, Njemačka (Septembar 2009)
  • 35. ESMO kongres, Milano, Italija (Oktobar 2010)
  • 1. Internacionalna konferencija o karcinomu glave i vrata i pluća, Atina, Grčka (Mart 2011)
  • Udruženi 16. ECCO/36. ESMO kongres, Štokholm, Švedska (Septembar 2011)
  • State of the Art Lung Cancer Preceptorship sastanak, Institut Gustave Roussy, Pariz, 24 – 25 Novembar 2011
  • Evropska konferencija o karcinomu dojke, Beč, Austrija (mart 2012)
  • Evropska konferencija o karcinomu pluća, Ženeva, Švicarska (april 2012)
  • 39 ESMO kongres, Madrid, Španija (Septembar 2014)
  • 14 Gallen International Breast Cancer Conference, Beč, Austrija (Mart 2012)
  • 7. dani BHAAAAS (Brcko, B&H, April 2015)
  • 1. Sarajevo zimska onkološka konferencija , Sarajevo, BiH (Decembar 2015)
  • 41. ESMO kongres, Kopenhagen, Danska (oktobar 2016)
  • 8 francusko-srpski onkološki kongres, Novi sad, Srbija (april 2017)
  • 42 ESMO kongres, Madrid, Spanija (Septembar 2017)
  • 3. Sarajevo zimska onkološka konferencija ( Sarajevo, BiH, Decembar 2017)
  • YOAI (Young oncologyst academy on immunotherapy, Udruženje onkologa BiH), Sarajevo, BiH (Mart 2018)
  • YOAI (Young oncologyst academy on immunotherapy, Udruženje onkologa BiH), Sarajevo, BiH (Septembar 2018)
  • 4. Sarajevo zimska onkološka konferencija ( Sarajevo, BiH, Novembar 2018)
  • YOAI (Young oncologyst academy on immunotherapy, Udruženje onkologa BiH), Sarajevo, BiH (Mart 2019)
  • 10 francusko-srpski onkološki kongres, Novi sad, Srbija (april 2019)
  • YOAI (Young oncologyst academy on immunotherapy, Udruženje onkologa BiH), Sarajevo, BiH (Septembar 2019)
  • ESMO kongres, Barselona, Španija (Septembar 2019)
  • Perceptorship kurs karcinom dojke, Lisabon/Porto, Portugal (oktobar 2019)
  • 5. Sarajevo zimska onkološka konferencija ( Sarajevo, BiH, Decembar 2019)

 

 

Pozvani predavač :

  • Tretman neželjenih efekata sistemske onkološke terapije. Udruženje onkologa BiH, Sarajevo, Decembar 2013.
  • Aktuelni pristup u liječenju karcinoma jajnika. Udruženje onkologa BiH, Sarajevo, Decembar 2014.
  • BHAAAS Days in BiH. Tretman karcinoma dojke sa negativnim receptorima (triple-negative) (Brcko, BiH April 2015.)
  • 1 kongres endokrinologa i dijabetologa BiH sa međunarodnim učešćem (Sarajevo, BiH, April 2015)
  • Neoadjuvantni sistemski tretman karcinoma dojke: izazovi, dobrobiti i aktuelne smjernice. Savremeni aspekti dijagnostike i liječenja karcinoma dojke, Medicinski fakultet Banjaluka, BiH (decembar 2019).

 

 

Učešće u kliničkim studijama:

  1. 2005 – CECOG/GIST 1.2.001,metastatic GIST, phase III (subInvestigator);

 

  1. 2005 – metastatic colorectal cancer phase II (subInvestigator);

 

  1. 2006 – CECOG/Core 1.2.001, metastatic colorectal cancer phase II (subInvestigator);

 

  1. 2008 –C-II-005, metastatic colorectal cancer phase II (subInvestigator);

 

  1. 2008 – CECOG /CORE 1.2.002, metastatic colorectal cancer phase II (subInvestigator);

 

  1. 2008 – CECOG/BC1.3.005, breast cancer phase III (subInvestigator);

 

  1. 2008 – BO20289, breast cancer phase III (subInvestigator);

 

  1. 2009 – BO20906, breast cancer phase III (subInvestigator);

 

  1. 2009 – B020231, breast cancer phase III (subInvestigator);

 

  1. 2010- MO22224, ovarian cancer phase III (subInvestigator);

 

  1. 2010 – BO22589 ,breast cancer phase III (subInvestigator );

 

  1. 2010 – BO21977, breast cancer phase III (subInvestigator);

 

  1. 2011- NCT01348126, lung cancer phase IIB/III (subInvestigator);

 

  1. 2014 – BO28407, breast cancer phase III (subInvestigator);

 

  1. 2014 – SB3-G31–BC, breast cancer phase III (Principal Investigator);

 

  1. 2014 – TRIO-020, breast cancer phase III (subInvestigator);

 

  1. 2015 – BO28984, lung cancer phase III (subInvestigator);

 

  1. 2016 – WO29522, breast cancer phase III (subInvestigator);

 

  1. 2016 – GO29058, breast cancer phase III (subInvestigator);

 

  1. 2016 – MYL1402O, lung cancer phase III (Principal Investigator);

 

  1. 2018 – MO39193, breast cancer phase III (Principal Investigator).

 

 

Lista publikacija:

  1. Pasic A, Ceric T,  Beslija S, Banjin M, Salkic B,  Sosevic A. Internet technology and multidisciplinary approach to cancer patients at Institute of oncology Sarajevo  ESO Conference on Managing cancer service   2005 Milan , Italy

 

  1. Salkić B, Banjin M, Sosevic A, Pasic A, Ceric T, Beslija S. Time to progression in patients with metastatic CRC treated with irinotecan or capecitabine as first line treatment (retrospective study). ESEC(ESMO Scientific & Educational Conference) 2005 Budapest Hungary

 

  1. Beslija S, Obralic N, Basic H, Tatarevic A, Mahic N, Banjin M, Cardzic A, Sosevic A, Pasic A, Ceric T, Salkic B. A Single Institution Randomized Trial of Taxotere (T) and Xeloda (X) Given in Combination vs. Taxotere (T) followed by Xeloda (X) after progression as First Line Chemotherapy (CT) for Metastatic Breast Cancer (MBC). EJC suppl.2005; 3(2):114-114.

 

  1. Beslija S, Obralic N, Basic H, Tatarevic A, Mahic N, Banjin M, Cardzic A, Sosevic A, Pasic A, Ceric T, Salkic B. Randomized trial of sequence vs. combination of capecitabine (X) and docetaxel (T): XT vs. T followed by X after progression as first-line therapy for patients (pts) with metastatic breast cancer (MBC). JCO, 2006; 24 (18, part1 suppl): 20S-20S.

 

  1. Beslija S, Obralic N, Basic H, Tatarevic A, Mahic N, Banjin M, Cardzic A, Sosevic A, Pasic A, Ceric T, Salkic B. Randomized trial of sequence vs. combination of capecitabine (X) and docetaxel (T): XT vs. T followed by X after progression as first-line therapy for patients (pts) with metastatic breast cancer (MBC). ASCO( American Asociation for clinical oncology) Annual Meeting Proceedings Part I. 2006 Vol 24, No. 18S (Supplement),: 571

 

  1. Beslija S, Banjin M, Jungic S, Obralic N, Kecman-Malcic G, Rakita I, Salkic B, Pasic A, Tinjic L, Smoljanovic V. Update phase II study results of capecitabine (X) + irinotecan (I) + bevacizumab (A) as first-line therapy for metastatic colorectal cancer (MCRC). JCO, 2009 ASCO Annual Meeting, Vol 27, No 15S, 2009:e15064;

 

  1. Hasanbegovic B, Basic H, OBralic N, Beslija S. Influence of taxane-based adjuvant chemotherapy in early breast cancer patients on disease free survival. Folia Medica Facultatis Medicinae Universitatis Saraeviensis;2012, Vol. 47 Issue 1, p79.

 

  1. Cerić T, Hasanbegović B, Bašić-Čabaravdić. Is individualy tailored therapy becomes reality? In: Lincender-Cvijetić L, Bašić-Čabaravdić H, urednici. Contemporary approach in breast cancer therapy. Sarajevo: BH Science and Art Academy, book 41; November 2012.

 

  1. Pašic A, Hasanbegović B, Bešlija S, Delić T. Informations for ovarian cancer patients. B&H Oncology Society, 2013.

 

  1. Bešlija S, Vrbanec D. Medicinska/internistička onkologija, 2014.
    1. Poglavlje Gastrointestinalne komplikacije
    2. Poglavlje Mučnina i povraćanje
    3. Poglavlje Metabolički problemi
    4. Poglavlje Karcinom tijela materice.

 

  1. Pasic, S. Beslija, A. Djuran, I. Sefic-Pasic, M. Banjin, T. Ceric, A. Rasic, Hasanbegovic, A. Jalovcic, E. Kapisazovic. Correlation between of expression of the enzyme topoisomerase I and p53 and result of irinotecan based therapy in patients with metastatic colorectal cancer. Annals of Oncology 26 (Supplement 4): iv1–iv100, 2015.

 

  1. Faruk Skenderi, Nurija Bilalovic, Vanesa Beslagic, Edina Balta, Berisa Hasanbegovic, Semir Beslija, Semir Vranic. Neuroendocrine carcinoma of the breast: A retrospective review 2005-2016. Folia medica 2016; 51 supp 1, p33.

 

  1. S Beslija, T Ceric, B Hasanbegovic, A Kurtović-Kozaric, A Pasic, N Mahic. 176P Clinical Outcomes of delayed start of trastuzumab treatment in patients with early breast cancer: ml25232 study. Annals of Oncology 28 (suppl 5), 2017.

 

  1. S Beslija, A Pasic, E Kapisazovic, B Hasanbegovic, E Sokolovic, F Skenderi, and T Ceric. Neoadjuvant trastuzumab + pertuzumab in HER2 positive breast cancer in a country with limited resources: Evaluation of complete pathological response in a real world practice. Journal of Clinical Oncology 2018 36:15_suppl, e12661-e12661.

 

  1. Rasic A, Sofic A, Beslija S, Rasic I, Hasanbegovic B. Effects of adding taxane to anthracycline-based neoadjuvant chemotherapy in locally advanced breast cancer. Med Glas (Zenica) 2019; 16(1):77-82

 

  1. Imamovic, D. , Bilalovic, N. , Skenderi, F. , Beslagic, V. , Ceric, T. , Hasanbegovic, B. , Beslija, S. and Vranic, S. A clinicopathologic study of invasive apocrine carcinoma of the breast: A single‐center experience. Breast J. 2018 . doi:10.1111/tbj.13140

 

  1. Eminagic Dz, Lokvancic A, Hasanbegovic B, Mekic-Abazovic A, Avdicevic A, et al. Efficacy and safety of local lysosime treatment in patients with oral mucositis after chemotherapy and radiotherapy. Acta Pharm. 69 (2019) 695-704.

 

  1. Dzinic SH, Mahdi Z, Bernarrdo MM, Vranic S, Beydoun H, Nahra N et al. Maspin differential expression patterns as a potential marker for targeted screening og oesophageal adenocarcinoma/gastroesophageal junction adneocarcinoma. PLoS ONE 2019; 14(4): e0215089.

 

  1. Banjin M. Melanom, 2018.
  2. Poglavlje Melanom kod pacijenata u trećoj životnoj dobi

 

  1. Bešlija S, Vrbanec D. Internistička onkologija, 2.prošireno izdanje 2019.
    1. Poglavlje Gastrointestinalne komplikacije
    2. Poglavlje Mučnina i povraćanje
    3. Poglavlje Metabolički problemi
    4. Poglavlje Karcinom tijela materice
    5. Poglavlje Onkološki tretman pacijenata sa dijabetesom
    6. Poglavlje Onkološki tretman pacijenata sa hepatalnom disfunkcijom
    7. Poglavlje Onkološki tretman pacijenata sa hepatitisom

Edukacija

  • Ph.D., Accounting & Finance, University of Strathclyde, Scotland
  • M.S.F., Finance, Boston College, Chestnut Hill, MA, 2006
  • M.B.A., Taxation, Golden Gate University, San Francisco, CA, 1983